Abstract
Background: Clinical practice guidelines for patients with primary biliary cholangitis (PBC) have been recently revised and implemented for well-established response criteria to standard first-line ursodeoxycholic acid (UDCA) therapy at 12 months after treatment initiation for the early identification of high-risk patients with inadequate treatment responses who may require treatment modification. However, there are only very limited data concerning the real-world clinical management of patients with PBC in Germany. Objective: The aim of this retrospective multicenter study was to evaluate response rates to standard first-line UDCA therapy and subsequent Second-line treatment regimens in a large cohort of well-characterized patients with PBC from 10 independent hepatological referral centers in Germany prior to the introduction of obeticholic acid as a licensed second-line treatment option. Methods: Diagnostic confirmation of PBC, standard first-line UDCA treatment regimens and response rates at 12 months according to Paris-I, Paris-II, and Barcelona criteria, the follow-up cut-off alkaline phosphatase (ALP) ≤ 1.67 × upper limit of normal (ULN) and the normalization of bilirubin (bilirubin ≤ 1 × ULN) were retrospectively examined between June 1986 and March 2017. The management and hitherto applied second-line treatment regimens in patients with an inadequate response to UDCA and subsequent response rates at 12 months were also evaluated. Results: Overall, 480 PBC patients were included in this study. The median UDCA dosage was 13.2 mg UDCA/kg bodyweight (BW)/d. Adequate UDCA treatment response rates according to Paris-I, Paris-II, and Barcelona criteria were observed in 91, 71.3, and 61.3% of patients, respectively. In 83.8% of patients, ALP ≤ 1.67 × ULN were achieved. A total of 116 patients (24.2%) showed an inadequate response to UDCA according to at least one criterion. The diverse second-line treatment regimens applied led to significantly higher response rates according to Paris-II (35 vs. 60%, p = 0.005), Barcelona (13 vs. 34%, p = 0.0005), ALP ≤ 1.67 × ULN and bilirubin ≤ 1 × ULN (52.1 vs. 75%, p = 0.002). The addition of bezafibrates appeared to induce the strongest beneficial effect in this cohort (Paris II: 24 vs. 74%, p = 0.004; Barcelona: 50 vs. 84%, p = 0.046; ALP < 1.67 × ULN and bilirubin ≤ 1 × ULN: 33 vs. 86%, p = 0.001). Conclusion: Our large retrospective multicenter study confirms high response rates following UDCA first-line standard treatment in patients with PBC and highlights the need for close monitoring and early treatment modification in high-risk patients with an insufficient response to UDCA since early treatment modification significantly increases subsequent response rates of these patients.
Highlights
Primary biliary cholangitis (PBC) is a rare chronic inflammatory biliary disease characterized by the progressive destruction of intrahepatic bile ducts, leading to cholestasis and subsequent liver damage
Primary biliary cholangitis may be associated with considerable morbidity despite recent advances in the management of this disease [2]
There is an unmet clinical need to improve the management of primary biliary cholangitis (PBC), in particular in patients with an inadequate response to standard first-line treatment with weight-based ursodeoxycholic acid (UDCA)
Summary
Primary biliary cholangitis (PBC) is a rare chronic inflammatory biliary disease characterized by the progressive destruction of intrahepatic bile ducts, leading to cholestasis and subsequent liver damage. Treatment with weight-based ursodeoxycholic acid (UDCA) has been proven to extend transplant-free survival and is recommended at a dosage of 13 to 15 mg UDCA/kg bodyweight (BW)/d as a standard first-line therapy by national and international PBC clinical practice guidelines [2,3,4]. These guidelines implemented the evaluation of specific response criteria at 12 months after the initiation of UDCA treatment for the early detection of high-risk patients with inadequate treatment responses who need treatment modification.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have